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ABSTRACT
COVID-19 pandemic has exaggerated the role of steroids in the standard of care despite minimum direct evidence of their
eﬃcacy in COVID-19 patients and their well-known adverse eﬀects. The literature abounds on the side eﬀects of steroids
aﬀecting diﬀerent organ systems of the body. COVID-19 patients, who are on long-term steroids, are more susceptible to their
adverse eﬀects. We, herein, brieﬂy review the potential uses and the adverse eﬀects of steroids on diﬀerent organ systems of
the body.
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The anti-inﬂammatory properties of corticosteroids are well
known. They modify lymphocyte/eosinophil functions and
minimise hypersensitivity reactions, mainly mediated via gene
transcription repression.1 During recent years, glucocorticoids
are becoming the standard of care in reducing inﬂammation
and regulation of immune responses, especially during the
pandemic of COVID-19 era. However, the incoherent use of
steroids in COVID-19 patients makes them more susceptible to
their adverse eﬀects. Steroid use may have some beneﬁts as
well as several adverse eﬀects, but front-line physicians often
recommend short-term glucocorticoid therapy with low to
medium doses with some beneﬁcial eﬀects among COVID-19
patients with severe clinical conditions. The synthetic forms of
corticosteroids have been documented with various side
eﬀects and toxicity depending on dosage, duration, and route of
administration.
The purpose of this study was to review the beneﬁcial or
delirious eﬀects of steroids in patients with COVID-19 infection.
During the present pandemic, there was initially a dilemma of
drug choice and reliable treatment options as no vaccine or
deﬁnitive treatment was available; hence, the steroids were
used as anti-inﬂammatory and immune modulators, especially
in the lung-related manifestations, despite the paucity of
evidence.2 The use of steroids in adult respiratory distress
syndrome (ARDS), with or without COVID-19, has been evaluated with conﬂicting results on safety and mortality.3
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The uncertainty persists on the eﬀectiveness of glucocorticoids
use in patients with COVID-19. Many guidelines for the treatment of such patients have stated that glucocorticoids are
either not recommended or contraindicated. Although in China,
glucocorticoids were used in severe cases. However, practice
4
varied widely across the world.
The recent WHO guidelines for COVID-19 did not recommend
the use of steroids as routine therapy unless there is a clear indication for its usage because of possible deleterious eﬀects and
increased mortality rate, which has been identiﬁed from studies
with other coronavirus infections and inﬂuenza.5 Few small
scale studies identiﬁed increased mortality with severe
COVID-19 infection.2 However, data also suggest the promising
eﬀects of steroid therapy in patients with COVID-19 patients,
who are on mechanical ventilation, though doubt still persists in
diabetic elderly patients.6 The UK Recovery trial4 and others
have used an individualised approach with diﬀerent steroid
7
dosages, depending upon the host response. The recovery trial
showed beneﬁt to patients in whom steroids (dexamethasone,
6 mg once daily for 10 days) were used with reduced 28-day
mortality (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to
0.81) as compared to usual care group. However, there was no
evidence of beneﬁt of steroid use in patients who were not
receiving respiratory support.4 Berton et al. identiﬁed reduced
mortality if steroids were used early (within the ﬁrst 14 days) in
the presence of severe respiratory failure despite standard
therapy.8 Some guidelines advocate for short course and
dosage of steroids in patients admitted in critical care. On the
contrary, other clinicians do not support steroid use because of
its hazardous side eﬀects.9 Similar meta-analysis identiﬁed
neither a beneﬁt on length of hospital stay, nor the mortality was
reduced in less sicker or critically ill patients.10 Even the dose did
not have any beneﬁcial eﬀect on patient outcomes, and the analysers identiﬁed heterogeneity of data; hence, results were not
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conclusive.10
The WHO recommends the use of steroids in COVID-19 patients,
5
who are under clinical trial. European Union (EU) regulatory
body also approves its use in critically ill COVID-19 patients.
Steroid treatment has shown promising results when used as lifesaving therapy among COVID-19 patients.9 A recently published
multicentre study from Spain on tocilizumab treatment alone,
demonstrated a reduction in mortality by 14.7%, (RRR 46. 7%),
and in combination with steroids demonstrated a reduced
mortality by 29.1% (RRR 72.8%).9 Lu et al. in a meta-analysis on
safety and eﬃcacy of steroids in COVID-19 cases gathered information from a vast number of studies; and concluded that steroid
use in COVID-19 patients did not reduce the risk of death among
sick cases, thought the duration and intensity of fever were
reduced. However, the length of hospital stay was not reduced.10
There have been increasing reports from across the world on
COVID-19-related multisystem inﬂammatory conditions (MISC), whose symptoms match with other inﬂammatory syndromes
like Kawasaki disease (KD) or toxic shock syndrome. There are no
widely accepted guidelines, but several organisations, like CDC
and RCPCH, published their own guidelines with a multidisciplinary team approach, and most cases need supportive care and
may need treatment with standard protocol for Kawasaki
disease, like intravenous immunoglobulin with or without
aspirin. Inotropics or steroids have also been used, as in recovery
trial.2,4
There are ample data on steroids crossing placenta with the
adverse eﬀects on fetus in utero, with some evidence showing
high possibility of mental and behavioural disorders in children,
who were exposed to steroids during their antenatal period.
Though data is not suﬃcient, however, the use of steroids for
severe COVID-19 pregnant women should be limited to those
cases where these are potentially needed and beneﬁcial.
The COVID-19 treatment guidelines panel recommends the use
of dexamethasone in mechanically ventilated COVID-19
patients and those who are on supplemental oxygen. It should be
cautiously administered with close monitoring to observe the
adverse eﬀects. The conﬂicting role of corticosteroid therapy in
COVID-19 demands extensive study and clinical trials to reach a
deﬁnitive conclusion; and the clinicians must consider individual
potential risks and beneﬁts of corticosteroids in patients with
COVID-19. The speciﬁc mechanisms by which steroids act on
sustained lung inﬂammation, the deﬁnition of the best drug to
use, and the appropriate treatment duration, are still objectives
of ongoing clinical trials.
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